Compare CRTO & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | EVO |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | France | Germany |
| Employees | 3649 | 4553 |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 874.8M | 994.5M |
| IPO Year | 2013 | N/A |
| Metric | CRTO | EVO |
|---|---|---|
| Price | $17.85 | $2.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $34.00 | $7.00 |
| AVG Volume (30 Days) | ★ 288.1K | 28.7K |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.95 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $2,296,692,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $5.54 | $10.05 |
| P/E Ratio | $116.07 | ★ N/A |
| Revenue Growth | ★ 27.65 | N/A |
| 52 Week Low | $15.58 | $2.31 |
| 52 Week High | $26.40 | $4.42 |
| Indicator | CRTO | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 51.61 | 42.69 |
| Support Level | $16.98 | $2.63 |
| Resistance Level | $19.81 | $3.82 |
| Average True Range (ATR) | 0.75 | 0.07 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 43.16 | 27.55 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.